Abstract: It has been reported in the literature that atopic dermatitis (AD) is an independent risk factor for keloid (KD), and the association between AD and the Th2 axis may increase the risk of KD development. Although dupilumabits for KD is not included in the prescribing information or guidelines, there have been reports of its efficacy in treating KD. This case represents the first reported instance of dupilumab treatment for KD in China. The patient had a 5-year history of severe atopic dermatitis and a 14-year history of keloids. Conventional treatments for AD yielded suboptimal results, and the patient was subsequently administered standard-dose dupilumab at regular intervals. After 10 weeks of treatment, the AD lesions had largely resolved with residual hyperpigmentation, while the erythema, hardness, and height of the KD showed improvement, with smaller keloids nearly resolved. At the one-month follow-up, there was no recurrence of AD, and the KD remained stable.

Key words: dupilumab, atopic dermatitis, keloid